Miscellaneous Ob/Gyn conditions:

Indications for: VYLEESI

Acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women and is not due to a coexisting medical or psychiatric condition, problems within the relationship, or adverse effect of a medication or other drug substance.

Limitations of Use:

Not for HSDD in postmenopausal women or in men. Not for sexual performance enhancement.

Adult Dosage:

Give by SC inj in abdomen or thigh as needed, at least 45mins before sexual activity. 1.75mg as a single daily dose. Max 1 dose per 24hrs or 8 doses per month. Discontinue if no improvement after 8 weeks.

Children Dosage:

Not established.

VYLEESI Contraindications:

Uncontrolled hypertension. Known cardiovascular disease.

VYLEESI Warnings/Precautions:

Consider patient’s cardiovascular risk before initiating and periodically during treatment, and ensure BP is well-controlled. High risk for cardiovascular disease: not recommended. Consider discontinuing if hyperpigmentation develops. Severe hepatic or renal impairment. Pregnancy: not recommended; discontinue if suspected. Nursing mothers.

VYLEESI Classification:

Melanocortin receptor agonist.

VYLEESI Interactions:

Avoid concomitant oral drugs that depend on threshold concentrations for efficacy (eg, antibiotics). Consider discontinuing if there is a delayed effect of concomitant oral drug when a quick onset is desired (eg, indomethacin). Avoid use with oral naltrexone-containing products intended to treat alcohol or opioid addiction.

Adverse Reactions:

Nausea, flushing, inj site reactions, headache, vomiting, cough, fatigue, hot flush, paraesthesia, dizziness, nasal congestion; focal hyperpigmentation (esp. with dark skin), transient increases in BP and reduction in HR.

Generic Drug Availability:


How Supplied:

Single-dose prefilled autoinjectors—4